Syndax Pharmaceuticals is a late-stage clinical development oncology company with a platform based on an epigenetic approach to overcoming the problem of resistance in cancer therapy. Syndax holds worldwide rights to entinostat, an oral, highly selective, class I histone deacetylase (HDAC) inhibitor, which inhibits cancer-relevant HDAC enzymes that contribute to epigenetic alterations driving cancer growth and drug tolerance. Targeted therapies represent an important class of agents used to treat both breast and lung cancers based on blocking the tumor’s addiction to growth promoting signals. Over time these therapies become ineffective due to acquired resistance. There are more than 300,000 individuals living with incurable breast or lung cancer in the United States. Entinostat’s unique pharmacokinetic properties, convenient oral dosing and HDAC selectivity, maximize the potential to safely combine with and extend the benefit of proven cancer targeted therapies. Syndax has a robust clinical program exploring the potential for entinostat to treat breast and lung cancer and additional types of cancer through collaboration with the National Cancer Institute.